Pharsight

Viekira Pak (copackaged) patents expiration

VIEKIRA PAK (COPACKAGED)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Dec, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(5 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(7 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(10 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(10 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(5 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(7 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(7 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

Viekira Pak (Copackaged) is owned by Abbvie Inc.

Viekira Pak (Copackaged) contains Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir.

Viekira Pak (Copackaged) has a total of 17 drug patents out of which 0 drug patents have expired.

Viekira Pak (Copackaged) was authorised for market use on 19 December, 2014.

Viekira Pak (Copackaged) is available in tablet;oral dosage forms.

Viekira Pak (Copackaged) can be used as treatment of hcv infection using dasabuvir, treatment of hcv infection using ombitasvir, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin., treatment of hcv infection using paritaprevir.

The generics of Viekira Pak (Copackaged) are possible to be released after 18 October, 2033.

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, riton...

Dosage: TABLET;ORAL

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic